1.
Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 rand...
by Pitisuttithum, Punnee
The Lancet infectious diseases, 2018-11, Vol.18 (11), p.1260-1268
2.
Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine
by Desai, Sajjad
Vaccine, 2018-09-05, Vol.36 (37), p.5519-5523
3.
4.
Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study
by Dbaibo, Ghassan
Vaccine, 2018-06-27, Vol.36 (28), p.4102-4111
5.
A decade of data: Adolescent vaccination in the vaccine safety datalink, 2007 through 2016
by Irving, Stephanie A
Vaccine, 2022-02-23, Vol.40 (9), p.1246-1252
6.
7.
Bacille Calmette-Guérin (BCG) vaccination at birth and antibody responses to childhood vaccines. A randomised clinical trial
by Nissen, Thomas Nørrelykke
Vaccine, 2017, Vol.35 (16), p.2084-2091
8.
9.
Virus-like particle-based human vaccines: quality assessment based on structural and functional properties
by Zhao, Qinjian
Trends in biotechnology (Regular ed.), 2013, Vol.31 (11), p.654-663
10.
SARS vaccines: where are we?
by Roper, Rachel L
Expert review of vaccines, 2009-07-01, Vol.8 (7), p.887-898
11.
Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial
by Bernstein, David I
Vaccine, 2015, Vol.34 (3), p.313-319
12.
Safety of immunization during pregnancy: A review of the evidence of selected inactivated and live attenuated vaccines
by Keller-Stanislawski, Brigitte
Vaccine, 2014, Vol.32 (52), p.7057-7064
13.
John D. Bailey retiring after more than 20 years of service to Vaccine
by van Dijk, Nicolette
Vaccine, 2022-06-09, Vol.40 (26), p.3483-3483
14.
15.
Publisher Correction: Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection
by Patone, Martina
Nature medicine, 2021-12, Vol.27 (12), p.2249-2249
16.
17.
Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania
by Bakari, Muhammad
Vaccine, 2011, Vol.29 (46), p.8417-8428
18.
From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
by Guy, Bruno
Vaccine, 2011, Vol.29 (42), p.7229-7241
19.
NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus , is safe and immunogenic in healthy adults
by Schmidt, Clint S
Vaccine, 2012, Vol.30 (52), p.7594-7600
20.
Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
by Glenn, Gregory M
Vaccine, 2012, Vol.31 (3), p.524-532
